Increased neovascularization in mice lacking tissue inhibitor of metalloproteinases-3

Investigative Ophthalmology and Visual Science

Volumn 52, Issue 9, 2011, Pages 6117-6123

  Ebrahem, Quteba ^a   Qi, Jian Hua ^a   Sugimoto, Masahiko ^a   Ali, Mariya ^a   Sears, Jonathan E ^a   Cutler, Alecia ^a   Khokha, Rama ^b   Vasanji, Amit ^c   Anand Apte, Bela ^a,c  

^a CLEVELAND CLINIC LERNER COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF TORONTO   (Canada)

^c LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TISSUE INHIBITOR OF METALLOPROTEINASE 3; VASCULOTROPIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CORNEA NEOVASCULARIZATION; EXTRACELLULAR MATRIX; HISTOPATHOLOGY; LASER; MOUSE; NONHUMAN; OCULAR BLOOD VESSEL; PATHOPHYSIOLOGY; PRIORITY JOURNAL; SUBRETINAL NEOVASCULARIZATION;

ANIMALS; CHOROIDAL NEOVASCULARIZATION; CORNEAL NEOVASCULARIZATION; DISEASE MODELS, ANIMAL; IMMUNOBLOTTING; IMMUNOPRECIPITATION; LASER COAGULATION; MATRIX METALLOPROTEINASE 3; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, KNOCKOUT; OPHTHALMOSCOPY; PHOSPHORYLATION; TISSUE INHIBITOR OF METALLOPROTEINASE-3; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 80051527752     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.10-5899     Document Type: Article

References (54)

1. Pepper MS, Montesano R, Mandriota SJ, Orci L, Vassalli JD. Angiogenesis: a paradigm for balanced extracellular proteolysis during cell migration and morphogenesis. Enzyme Protein. 1996; 49:138-162.
2. Matrisian LM. The matrix degrading metalloproteinases. Bioessays. 1992;14:455-463.
3. Lafleur MA, Handsley MM, Edwards DR. Metalloproteinases and their inhibitors in angiogenesis. Expert Rev Mol Med. 2003;5:1-39.
4. Werb Z, Vu TH, Rinkenberger JL, Coussens LM. Matrix-degrading proteases and angiogenesis during development and tumor formation. APMIS. 1999;107:11-18.
5. Hiraoka N, Allen E, Apel IJ, Gyetko MR, Weiss SJ. Matrix metalloproteinases regulate neovascularization by acting as pericellular fibrinolysins. Cell. 1998;95:365-377.
6. Stetler-Stevenson W, Corcoran M. Tumor angiogenesis: functional similarities with tumor invasion. EXS. 1997;79:413-418.
7. Stetler-Stevenson WG. Matrix metalloproteinases in angiogenesis: a moving target for therapeutic intervention. J Clin Invest. 1999; 103:1237-1241.
8. Apte SS, Olsen B, Murphy G. The gene structure of tissue inhibitor of metalloproteinases (TIMP)-3 and its inhibitory activities define the distinct TIMP gene family. J Biol Chem. 1995;270:14313-14318.
9. Murphy G. The regulation of connective tissue metalloproteinases by natural inhibitors. In: AAS 35: Progress in Inflammation Research and Therapy. Basel: Birkhauser; 1991:69-76.
10. Anand-Apte B, Pepper MS, Voest E, et al. Inhibition of angiogenesis by tissue inhibitor of metalloproteinase-3. Invest Ophthalmol Vis Sci. 1997;38:817-823.
11. Qi JH, Ebrahem Q, Moore N, et al. A novel function for tissue inhibitor of metalloproteinases-3 (TIMP3): inhibition of angiogenesis by blockage of VEGF binding to VEGF receptor-2. Nat Med. 2003;9:407-415.
12. Haigh JJ. Role of VEGF in organogenesis. Organogenesis. 2008;4: 247-256.
13. Haigh JJ, Morelli PI, Gerhardt H, et al. Cortical and retinal defects caused by dosage-dependent reductions in VEGF-A paracrine signaling. Dev Biol. 2003;262:225-241.
14. Stalmans I, Ng YS, Rohan R, et al. Arteriolar and venular patterning in retinas of mice selectively expressing VEGF isoforms. J Clin Invest. 2002;109:327-336.
15. Saint-Geniez M, Kurihara T, Sekiyama E, Maldonado AE, D'Amore PA. An essential role for RPE-derived soluble VEGF in the maintenance of the choriocapillaris. Proc Natl Acad Sci U S A. 2009;106: 18751-18756.
16. Marneros AG, Fan J, Yokoyama Y, et al. Vascular endothelial growth factor expression in the retinal pigment epithelium is essential for choriocapillaris development and visual function. Am J Pathol. 2005;167:1451-1459.
17. Janssen A, Hoellenriegel J, Fogarasi M, et al. Abnormal vessel formation in the choroid of mice lacking tissue inhibitor of metalloprotease-3. Invest Ophthalmol Vis Sci. 2008;49:2812-2822.
18. Stone EM, Sheffield VC, Hageman GS. Molecular genetics of agerelated macular degeneration. Hum Mol Genet. 2001;10:2285-2292.
19. Chen W, Stambolian D, Edwards AO, et al. Genetic variants near TIMP3 and high-density lipoprotein-associated loci influence susceptibility to age-related macular degeneration. Proc Natl Acad Sci U S A. 2010;107:7401-7406.
20. Leco KJ, Waterhouse P, Sanchez OH, et al. Spontaneous air space enlargement in the lungs of mice lacking tissue inhibitor of metalloproteinases-3 (TIMP-3). J Clin Invest. 2001;108:817-829.
21. Mohammed FF, Smookler DS, Taylor SE, et al. Abnormal TNF activity in Timp3_/_ mice leads to chronic hepatic inflammation and failure of liver regeneration. Nat Genet. 2004;36:969-977.
22. Seeliger MW, Beck SC, Pereyra-Munoz N, et al. In vivo confocal imaging of the retina in animal models using scanning laser ophthalmoscopy. Vision Res. 2005;45:3512-3519.
23. Tobe T, Ortega S, Luna JD, et al. Targeted disruption of the FGF2 gene does not prevent choroidal neovascularization in a murine model. Am J Pathol. 1998;153:1641-1646.
24. Oshima Y, Oshima S, Nambu H, et al. Increased expression of VEGF in retinal pigmented epithelial cells is not sufficient to cause choroidal neovascularization. J Cell Physiol. 2004;201:393-400.
25. Schwesinger C, Yee C, Rohan RM, et al. Intrachoroidal neovascularization in transgenic mice overexpressing vascular endothelial growth factor in the retinal pigment epithelium. Am J Pathol. 2001;158:1161-1172.
26. Tee LB, Penrose MA, O'Shea JE, Lai CM, Rakoczy EP, Dunlop SA. VEGF-induced choroidal damage in a murine model of retinal neovascularisation. Br J Ophthalmol. 2008;92:832-838.
27. Lambert V, Wielockx B, Munaut C, et al. MMP-2 and MMP-9 synergize in promoting choroidal neovascularization. FASEB J. 2003;17:2290-2292.
28. Mayranpaa MI, Trosien JA, Fontaine V, et al. Mast cells associate with neovessels in the media and adventitia of abdominal aortic aneurysms. J Vasc Surg. 2009;50:388-395, discussion 395-386.
29. Sun J, Sukhova GK, Yang M, et al. Mast cells modulate the pathogenesis of elastase-induced abdominal aortic aneurysms in mice. J Clin Invest. 2007;117:3359-3368.
30. Sun J, Zhang J, Lindholt JS, et al. Critical role of mast cell chymase in mouse abdominal aortic aneurysm formation. Circulation. 2009;120:973-982.
31. Tsuruda T, Kato J, Hatakeyama K, et al. Adventitial mast cells contribute to pathogenesis in the progression of abdominal aortic aneurysm. Circ Res. 2008;102:1368-1377.
32. de Jong PT. Age-related macular degeneration. N Engl J Med. 2006;355:1474-1485.
33. Edwards AO, Ritter R 3rd, Abel KJ, Manning A, Panhuysen C, Farrer LA. Complement factor H polymorphism and age-related macular degeneration. Science. 2005;308:421-424.
34. Hageman GS, Anderson DH, Johnson LV, et al. A common haplotype in the complement regulatory gene factor H (HF1/CFH) predisposes individuals to age-related macular degeneration. Proc Natl Acad Sci U S A. 2005;102:7227-7232.
35. Haines JL, Hauser MA, Schmidt S, et al. Complement factor H variant increases the risk of age-related macular degeneration. Science. 2005;308:419-421.
36. Jager RD, Mieler WF, Miller JW. Age-related macular degeneration. N Engl J Med. 2008;358:2606-2617.
37. Klein R, Peto T, Bird A, Vannewkirk MR. The epidemiology of age-related macular degeneration. Am J Ophthalmol. 2004;137: 486-495.
38. Klein RJ, Zeiss C, Chew EY, et al. Complement factor H polymorphism in age-related macular degeneration. Science. 2005;308: 385-389.
39. Scholl HP, Fleckenstein M, Fritsche LG, et al. CFH, C3 and ARMS2 are significant risk loci for susceptibility but not for disease progression of geographic atrophy due to AMD. PLoS ONE. 2009;4:e7418.
40. De La Paz MA, Pericak-Vance MA, Lennon F, Haines JL, Seddon JM. Exclusion of TIMP3 as a candidate locus in age-related macular degeneration. Invest Ophthalmol Vis Sci. 1997;38:1060-1065.
41. Boekhoorn SS, Isaacs A, Uitterlinden AG, et al. Polymorphisms in the vascular endothelial growth factor gene and risk of age-related macular degeneration: the Rotterdam Study. Ophthalmology. 2008;115:1899-1903.
42. Weber BH, Vogt G, Pruett RC, Stohr H, Felbor U. Mutations in the tissue inhibitor of metalloproteinase-3 (TIMP-3) in patients with Sorsby's fundus dystrophy. Nat Genet. 1994;8:352-356.
43. Langton KP, McKie N, Curtis A, et al. A novel tissue inhibitor of metalloproteinases-3 mutation reveals a common molecular phenotype in Sorsby's fundus dystrophy. J Biol Chem. 2000;275: 27027-27031.
44. Langton KP, McKie N, Smith BM, Brown NJ, Barker MD. Sorsby's fundus dystrophy mutations impair turnover of TIMP-3 by retinal pigment epithelial cells. Hum Mol Genet. 2005;14:3579-3586.
45. Weber BH, Lin B, White K, et al. A mouse model for Sorsby fundus dystrophy. Invest Ophthalmol Vis Sci. 2002;43:2732-2740.
46. Baba T, Grebe R, Hasegawa T, et al. Maturation of the fetal human choriocapillaris. Invest Ophthalmol Vis Sci. 2009;50:3503-3511.
47. Hasegawa T, McLeod DS, Bhutto IA, et al. The embryonic human choriocapillaris develops by hemo-vasculogenesis. Dev Dyn. 2007; 236:2089-2100.
48. Saint-Geniez M, D'Amore PA. Development and pathology of the hyaloid, choroidal and retinal vasculature. Int J Dev Biol. 2004;48: 1045-1058.
49. Saint-Geniez M, Maldonado AE, D'Amore PA. VEGF expression and receptor activation in the choroid during development and in the adult. Invest Ophthalmol Vis Sci. 2006;47:3135-3142.
50. Kassiri Z, Defamie V, Hariri M, et al. Simultaneous transforming growth factor beta-tumor necrosis factor activation and cross-talk cause aberrant remodeling response and myocardial fibrosis in Timp3-deficient heart. J Biol Chem. 2009;284:29893-29904.
51. Norrby K. Mast cells and angiogenesis. APMIS. 2002;110:355-371.
52. Coussens LM, Raymond WW, Bergers G, et al. Inflammatory mast cells up-regulate angiogenesis during squamous epithelial carcinogenesis. Genes Dev. 1999;13:1382-1397.
53. Amour A, Slocombe P, Webster A, et al. TNF-alpha converting enzyme (TACE) is inhibited by TIMP-3. FEBS Lett. 1998;435:39-44.
54. Cruz-Munoz W, Kim I, Khokha R. TIMP-3 deficiency in the host, but not in the tumor, enhances tumor growth and angiogenesis. Oncogene. 2006;25:650-655.